Intrahospial Preparation and Stability of Adriamycin Encapsulated Liposome

Abstract

Adriamycin (ADM), an important antitumor agent with a wide spectrum, has dosage limitation in its clinical use because of its dose-related cardiotoxicity. One of the approaches to minimize this toxicity is to encapsulate ADM in liposomes.
We have developed an injectable liposomal preparation in which ADM is entrapped (ADMLip) for intrahospital use. ADM was entrapped in negatively charged liposomes which were composed of egg phosphatidylcholine, cholesterol, and phosphatidylserine (molar ratio of 5: 4: 1). Effective ADM entrapment (rate) in our intrahospital preparation was approximately 60%. The liposomal particle size, as measured by the dynamic light scattering method, was 203±90 nm. ADM-Lip was sterilized through a polycarbonate membrane filter with a pore diameter of 0.2μm.